Professor Philip Sloan has recently joined the growing AMLo Biosciences executive team as Chief Histopathologist.
He will work closely with Professor Penny Lovat, our Chief Scientific Officer, to complete the histopathological scoring of ~2,000 samples of melanoma from around the world. These cohorts will complete the pivotal evidence package for the UK NICE submission and the FDA pre-sub in the USA. Phil is the ideal choice to join AMLo as he has been involved in the identification and proof of AMBRA1 and loricrin as dual biomarkers for melanoma progression, alongside Professor Lovat and the AMLo team, for a number of years.
Philip’s extensive contacts and international profile will help AMLo to further develop the AMBLor evidence base for inclusion in international melanoma guidance. He will also support the AMLo scientific and commercial team at international meetings to raise awareness about AMBLor and the roles of AMBRA1 and loricrin in early stage melanoma prognosis.
About Philip Sloan
Professor Philip Sloan is a practicing pathologist specialising in head & neck, skin and bone & soft tissue pathology. Philip currently engages in research into advanced cellular therapies and novel diagnostic tests. He was director of the CEPA Biobank and co-director of the EPSRC/MRC Molecular Pathology Node, that merged in 2021 to form NovoPath. Philip is a member of the advisory scientific board of AMLo engaged in developing a prognostic test for early stage melanoma. He has a particular interest and expertise in Quality Assurance for laboratory medicine and clinical trials.
Philip Sloan graduated from Newcastle University in 1974, gained his PhD from the University of Bristol in 1978. He was Professor of Experimental Pathology at the University of Manchester and R&D Director of CMHT until 2007. He has authored or co-authored over 300 peer reviewed publications and five books. Currently he a member of the WHO collaborating group for OMPDs and cancer, and is a lead author for ICCR guidelines.
Philip is particularly enthusiastic about working with industry partners as well as academic researchers, for patient benefit.
Professor Philip Sloan
Department of Cellular Pathology
Queen Victoria Road
Newcastle upon Tyne Hospitals NHS Foundation Trust